| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_361e779ab94fb0a7a7738acec62ff2f5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2242
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-58 |
| filingDate |
2021-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbe51a81802d90e27d53eef37f91aa73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39edc2e6d548ff63b4741cef968f43cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62e50d222db89c0813ce40cef092ae48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd96ea00fdb751018eee875556e046c8 |
| publicationDate |
2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11154593-B2 |
| titleOfInvention |
CNP prodrugs with large carrier moieties |
| abstract |
The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11224661-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311604-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389510-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11413351-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11564974-B2 |
| priorityDate |
2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |